Tuesday, July 24, 2012
Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study testing CRLX101 in platinum-resistant ovarian cancer. The study is designed to test the drug, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in patients whose disease has progressed following standard first-line platinum-based therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.